Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 2, 2011, Pages 125-131

  Mineur, L ^a   Sabatier, R ^a   Kirscher, S ^a   Plat, F ^a   Goubely, Y ^a   Molinari, N ^b  

^a INSTITUT SAINTE CATHERINE   (France)

^b Université de Nîmes ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PRACTICE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; LOW DRUG DOSE; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 80052331742     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.11.005     Document Type: Article

References (17)

1. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J clin Oncol 2004;22(2):229-37.
2. Colucci G, Gebbia V, Paoletti G et al. Phase III randomised trial of FOLFIRI versus FOLFOX4 in treatment of Advanced Colorectal Cancer: A multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale. J clin Oncol 23:4866-75.
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42.
5. E. Van Cutsem, M. Nowacki, I. Lang, S. Cascinu, I. Shchepotin, J. Maurel, P et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the firstline treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial Journal of Clinical Oncology, Annual Meeting Proceedings. Vol 25, No 18S (June 20 Supplement), 2007:4000.
6. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan Study Group. N Engl J Med 2000;343:905-14.
7. 2m) according to toxicity prognostic factors. Anticancer Drugs 2004;15(9):835-41.
8. Duffour J, Gourgou S, Desseigne F, et al. Multicenter phase II study sing increasing doses or irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. Cancer Chemother Pharmacol 2007;60(3):383-9.
9. Ychou M, Raoul JL, Desseigne F, Borel C, Caroli-Bosc FX, Jacob JH, et al. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol 2002;50(5):383-91.
10. Ducreux M, Raoul JL, Marti P, Merrouche Y, Tigaud JM, Rebischung C., et al. High dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Oncology 2008;74:17-24.
11. Maughan TS, Kerr DJ, Ledermann JA, Seymour MT, Topham C, McArdle C, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicenter randomised trial. Lancet 2003;361: 457-64.
12. F. Maindrault-Goebel, G. Lledo, B. Chibaudel, L. Mineur, T. Andre, M. Bennamoun, M et al. GERCOR OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. J Clin Oncol 2006 ASCO Annual Meeting Proceedings, 2006:24, 3504, [18S].
13. Del Rio M, Molina F, Bascoul-Mollevi C Copois V, Bibeau F, Chalbos P et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007;25:773-80.
14. Maitland ML, DiRienzo A, Ratain MJ et al. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol 2006;24:2151-7.
15. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005;11:1226-36.
16. Phelip JM. Cetuximab and combination chemotherapy as firstline therapy in treating patients with colorectal cancer that has spread to the liver and/or Lung. http://clinicaltrials.gov.
17. Rivoire M., Thezenas S., Rebischung C., Viret F., Guimbaud R., Francois E. et al. Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP) J Clin Oncol, 2008 ASCO Annual Meeting Proceedings. 26, No 15S (May 20 Supplement), 2008:4075.